No Data
Alcon's Solid Performance and Growth Momentum Justify Buy Rating Despite FX Headwinds
Alcon's Growth Trajectory: Positive Survey Insights and Product Launches Drive Buy Rating
Express News | Sight Sciences Shares Are Trading Higher After the Company Announced a $34 Million Patent Infringement Verdict Against Alcon and Its Hydrus Microstent
Sight Sciences Says It Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump
Sight Sciences (SGHT) said Monday it has received a jury trial verdict of $34 million related to the patent-infringement case it filed in September 2021 against Alcon (ALC) in the US District Court fo
Express News | Sight Sciences Announces $34M Patent Infringement Verdict Against Alcon And Its Hydrus Microstent For Microinvasive Glaucoma Surgery; Monetary Damages Comprised Of $5.5M In Lost Profits And $28.5M In Royalty Damages For Sales Of The Hydrus Microstent For
Express News | Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and Its Hydrus Microstent for Microinvasive Glaucoma Surgery